San Carlos – October 12, 2026 -- Fierce MedTech has named Noah Medical one of its 2023 "Fierce 15" medical technology companies, citing the growth of the Galaxy System, the company's first commercial platform for robotic navigated bronchoscopy.
Fierce MedTech credited Noah Medical's long-term plan to improve early diagnosis and treatment across multiple indications. The Galaxy System is a fully image-integrated platform aimed at minimally invasive early lung cancer diagnosis.
Galaxy System reports 100% tool-in-lesion accuracy in human trial
Noah Medical reports that the Galaxy System achieved 100% successful navigation to lesion, 100% diagnostic yield and 95% tool-in-lesion accuracy in a preclinical trial. In a human trial, it reported 100% tool-in-lesion accuracy and 90-95% diagnostic yield. The figures are company-reported, and the source gives no trial sizes.
Platform combines tomosynthesis with a disposable single-use bronchoscope
The system, designed with physicians, uses proprietary integrated tomosynthesis (TiLT+ Technology) with augmented fluoroscopy. It also has a disposable single-use bronchoscope with always-on vision. Its compact footprint is meant to fit into most bronchoscopy suites.
Galaxy adds Medtech Breakthrough win and Fierce Innovation Awards finalist spot
The Galaxy System was also named a Medtech Breakthrough winner and a finalist in the 2023 Fierce Innovation Awards: Life Sciences Edition.
Noah Medical CEO Jian Zhang credited the company's team and its growing list of hospital partners for establishing Galaxy as a leader in minimally invasive early lung cancer diagnosis. Fierce MedTech senior editor Conor Hale said the honorees show the industry's ability to turn "cutting-edge ideas into meaningful outcomes" at scale.
Noah Medical is based in Silicon Valley and backed by institutional investors, though the source does not name them.